Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Lacolle Peters
Observed institutions:
City Of Hope National Medical Center,
City of Hope
OpenAlex ID:
A5026060972
Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade
2023
·
Matthew Mei
, Lu Chen
, et al.
·
Blood
·
44
PDF
Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial
2022
·
Alex F Herrera
, Lu Chen
, et al.
·
The Lancet Haematology
·
41
Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study
2024
·
Alex F Herrera
, Jasmine Zain
, et al.
·
The Lancet Haematology
·
23
Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma
2019
·
Alex F. Herrera
, Lu Chen
, et al.
·
Blood
·
22
Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma
2023
·
James Godfrey
, Matthew Mei
, et al.
·
Haematologica
·
21
PDF
Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Expressing Peripheral T-Cell Lymphomas
2021
·
Alex F. Herrera
, Jasmine Zain
, et al.
·
Blood
·
20
Consolidation with Nivolumab and Brentuximab Vedotin after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma
2020
·
Alex F. Herrera
, Lu Chen
, et al.
·
Blood
·
20
Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
2022
·
Alex F. Herrera
, Lu Chen
, et al.
·
Blood
·
18
Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high‐risk relapsed/refractory Hodgkin lymphoma
2025
·
Matthew Mei
, Joycelynne Palmer
, et al.
·
HemaSphere
·
11
PDF
Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma
2024
·
Tamer Othman
, Paul Frankel
, et al.
·
Haematologica
·
10
Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Positive Peripheral T-Cell Lymphomas
2019
·
Alex F. Herrera
, Jasmine Zain
, et al.
·
Blood
·
9
Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma
2024
·
Swetha Kambhampati Thiruvengadam
, Matthew G. Mei
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
5
Nivolumab Plus ICE As First Salvage Therapy in High-Risk Relapsed/Refractory Hodgkin Lymphoma
2022
·
Matthew Mei
, Joycelynne Palmer
, et al.
·
Blood
·
5
Pembrolizumab Plus Vorinostat Induces Responses in Patients with Hodgkin Lymphoma Who Are Refractory to Prior PD-1 Blockade
2021
·
Alex F. Herrera
, Lu Chen
, et al.
·
Blood
·
2
Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma
2022
·
Swetha Kambhampati
, Matthew Mei
, et al.
·
Blood
·
1
Atezolizumab Combined with Immunogenic Salvage Chemoimmunotherapy (R-GemOx+Atezo) in Patients with Transformed Diffuse Large B-Cell Lymphoma
2021
·
Alex F. Herrera
, Tamer Othman
, et al.
·
Blood
·
1
Polatuzumab Vedotin Combined With R ‐ ICE ( PolaR ‐ ICE ) as Second‐Line Therapy in Diffuse Large B ‐Cell Lymphoma
2026
·
Geoffrey Shouse
, Matthew Matasar
, et al.
·
American Journal of Hematology
P111: Phase I Trial of Brentuximab Vedotin plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma
2022
·
Swetha Kambhampati
, Matthew Mei
, et al.
·
HemaSphere
Show more works
View as search
Works count:
18
Citation count:
253
H-index:
10
I10-index:
10
Year
Topic
Type
